Mission Statement

We are Developing Innovative Drugs for Metabolic Diseases.

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, with a focus on non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, Imeglimin, that targets mitochondrial dysfunction, is now marketed under the name TWYMEEG® for the treatment of type 2 diabetes in Japan.

On the web